This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== Packaging materials == Flexible films are commonly used for products such as fresh produce, meats, fish and bread seeing as they provide suitable permeability for gases and water vapor to reach the desired atmosphere. Pre-formed trays are formed and sent to the food packaging facility where they are filled. The package headspace then undergoes modification and sealing. Pre-formed trays are usually more flexible and allow for a broader range of sizes as opposed to thermoformed packaging materials as different tray sizes and colors can be handled without the risk of damaging the package. Thermoformed packaging however is received in the food packaging facility as a roll of sheets. Each sheet is subjected to heat and pressure, and is formed at the packaging station. Following the forming, the package is filled with the product, and then sealed. The advantages that thermoformed packaging materials have over pre-formed trays are mainly cost-related: thermoformed packaging uses 30% to 50% less material, and they are transported as rolls of material. This will amount in significant reduction of manufacturing and transportation costs. When selecting packaging films for MAP of fruits and vegetables the main characteristics to consider are gas permeability, water vapor transmission rate, mechanical properties, transparency, type of package and sealing reliability.
After a fire at the Washington National Records Center, unclassified, non-privacy-protected, water-damaged records were frozen on site and vacuum freeze-dried off site; most of the paper-based records looked essentially the same after drying.
In those with prediabetes, alpha-glucosidase inhibitors such as acarbose may delay or reduce the risk of type 2 diabetes when compared to placebo, however there was no conclusive evidence that acarbose improved cardiovascular mortality or cardiovascular events, according to a 2018 Cochrane review. In those with prediabetes, pioglitazone may delay or reduce the risk of developing type 2 diabetes compared to placebo or no intervention, but no difference was seen compared to metformin, and data were missing on mortality and complications and quality of life, according to a 2020 Cochrane review. In those with prediabetes, there was insufficient data to draw any conclusions on whether SGLT2 inhibitors may delay or reduce the risk of developing type 2 diabetes, according to a 2016 Cochrane review.
Sources: en.wikipedia.org
=== 2018–present: The feud reignites === The peace between the two rappers found itself to be short-lived as 50 Cent would reignite the feud in 2015 when Ja Rule gave a feedback to a social follower via Twitter over a similar feud between Meek Mill and Drake. Enraged, 50 Cent later responded with photos and comments via Instagram, only siding with Drake. The feud would fully resurface two years later when 50 Cent mocked Ja Rule's involvement in that year's ill-fated Fyre Festival in which numerous concertgoers were scammed in a poorly conceived event based on Ja Rule's business relationship with fraudster Billy McFarland. Jackson would further continue reigniting tensions on January 18, 2018; when he would once again attack Ja Rule on Big Boy's Neighborhood during an interview. Ja Rule immediately responded to 50 Cent's comments on twitter the very next day. Further adding to the hostility; Jackson would prank Ja Rule in October 2018 by purchasing 200 discounted front-row tickets for an upcoming show of his in Arlington, Texas for a total of US$3,000 via Groupon. Jackson later confirmed on social media that he bought the tickets with the express intention of forcing Ja Rule to perform in front of rows of empty seats. Tensions would briefly reignite between Eminem and Ja Rule as he would attack him on the track "The Ringer" from his 2018 album Kamikaze. During Eminem's followup response to Machine Gun Kelly's diss track "Rap Devil", he included several lines claiming to have taken part in ending the careers of both Ja Rule and Benzino on Killshot.
Hyperforin is a phytochemical produced by some of the members of the plant genus Hypericum, notably Hypericum perforatum (St John's wort). Hyperforin may be involved in the pharmacological effects of St. John's wort, specifically in its antidepressant effects. Meta-analyses of clinical trials suggest that H. perforatum is as effective as SSRIs for treating mild to moderate depression and is better tolerated, although findings are limited by short study durations. Hyperforin is found in significant amounts only in H. perforatum, where it accumulates as a probable plant defense compound, with modern carbon dioxide extraction methods used to isolate it from mixtures containing related compounds like adhyperforin.
In response to the attacks, Hezbollah made its deepest incursion into Israeli territory at the time by launching drone attacks into the city of Acre targeting two IDF bases. On 5 May, an Israel airstrike on a house in the Lebanese village of Meiss Ej Jabal killed four civilians. In retaliation, Hezbollah fired dozens of rockets at the Israeli town of Kiryat Shmona. On 6 May, two reservist Israeli soldiers of the 98th Paratroopers Division's 655th Battalion were killed by a Hezbollah drone attack near Metula, northern Israel, bringing the IDF death toll to 18. Hezbollah also launched 30 rockets at the Golan Heights, damaging houses in Kidmat Tzvi. The IDF struck 15 Radwan targets in al-Lwaiza, southern Lebanon, and a Hezbollah compound in Sefri, near Baalbek. Lebanese media said that the strike destroyed a factory and injured three people. On 8 May, Israeli airstrikes in southern Lebanon killed two Hezbollah and three PIJ members. The next day an Israeli airstrike on a car near the village of Bafliyeh killed four Hezbollah members. On 10 May, Israeli airstrikes on two villages in the Marjeyoun District killed a Hezbollah member in Aedsheet and a PIJ member in Blida, respectively. On the same day, another Israeli airstrike on the town of Tayr Harfa killed two civilians who were carrying out repairs on a local cell tower. On 14 May, an Israeli airstrike on a house in the village of Meiss Ej Jabal killed a member of Hezbollah and injured one other person.
Sources: en.wikipedia.org
The theory further states that removing opiate precursors from a child's diet may allow time for these behaviors to cease, and neurological development in very young children to resume normally. As of 2021, reliable studies have not demonstrated the benefit of gluten-free diets in the treatment of autism. In the subset of people who have gluten sensitivity there is limited evidence that suggests that a gluten-free diet may improve some autistic behaviors.
After Liautaud graduated second to last in his class at Elgin Academy in 1982, his father gave him a choice to either join the Army or start a business. Although his father wanted him to enlist, the younger Liautaud chose the latter, and his father agreed to loan him $25,000 in exchange for a 48% stake in the business. Initially, Liautaud wanted to open a hot dog stand, but after visiting numerous such stands throughout the summer of 1982, he realized the $25,000 would not be enough for such a venture. After a chance encounter at a sandwich shop, he realized that he could open a sandwich shop within his available budget by purchasing premium meats at a neighborhood market and baking his own bread. With the help of his family as tasters, he decided to put four sandwiches on his original menu. Paying $200 a month in rent, Liautaud could afford only used equipment consisting of a refrigerator, a chest freezer, an oven, and a meat slicer. On January 13, 1983, Jimmy John's Gourmet Sandwiches opened in Charleston, Illinois. Due to the poor location of his first store, Liautaud decided to include delivery of his sandwiches to boost sales. He began by bringing samples door-to-door to the dorms of nearby Eastern Illinois University, which he had attended for one semester. By the end of his first year, the restaurant started making a profit. In April 1985, Liautaud bought out his father's interest in the business, becoming the sole owner. In 1986, he opened his second store in Macomb, Illinois, and in 1987, he opened a third in Champaign, Illinois.
Embryonic mitochondrial transplant and protofection have been proposed as a possible treatment for inherited mitochondrial disease, and allotopic expression of mitochondrial proteins as a radical treatment for mtDNA mutation load. In June 2018 Australian Senate's Senate Community Affairs References Committee recommended a move towards legalising MRT. Research and clinical applications of MRT were overseen by laws made by federal and state governments. State laws were, for the most part, consistent with federal law. In all states, legislation prohibited the use of MRT techniques in the clinic, and except for Western Australia, research on a limited range of MRT was permissible up to day 14 of embryo development, subject to a license being granted. In 2010, the Hon. Mark Butler MP, then Federal Minister for Mental Health and Ageing, had appointed an independent committee to review the two relevant acts: the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human Embryos Act 2002. The committee's report, released in July 2011, recommended the existing legislation remain unchanged Currently, human clinical trials are underway at GenSight Biologics (ClinicalTrials.gov # NCT02064569) and the University of Miami (ClinicalTrials.gov # NCT02161380) to examine the safety and efficacy of mitochondrial gene therapy in Leber's hereditary optic neuropathy.
=== Clipse Week with Genius === Clipse collaborated with lyrics website and media company Genius for a series named Clipse Week. It began with a Genius Verified video for "Chains & Whips" on July 11, 2025. Verified is a series in which artists explain their songs' lyrical meaning and inspiration. Malice spoke about his faith, his time away from Clipse, and what made him return; he also commented on the perception that Pusha T is too outspoken about industry peers, arguing that his brother's statements are actually mild: "I truly admire his restraint. People think he goes over the top and just with me knowing where all the bodies are buried, I admire his restraint." Pusha T revealed that the chorus was started by Williams when the duo was stuck during the writing process. On the same day, Malice wrote official annotations for each track on Let God Sort Em Out through his verified Genius account. A Genius Verified video for "Ace Trumpets" was released on July 14.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.